Clinical scienceEvolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives?
References (24)
Interspecies scaling of regional drug delivery
J Pharmacol Sci
(1986)- et al.
Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer
Ann Oncol
(2007) - Chua TC, Liauw W, Saxena A, et al. Evolution of loco-regional treatment for peritoneal carcinomatosis: single-centre...
- et al.
When are randomised trials unnecessary?Picking signal from noise
BMJ
(2007) Epithelial appendiceal neoplasms
Cancer J
(2009)- et al.
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study
J Clin Oncol
(2010) - et al.
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma
J Clin Oncol
(2006) - et al.
Lymph node metastases in diffuse malignant peritoneal mesothelioma
Ann Surg Oncol
(2010) Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal
Ann Surg Oncol
(2010)- et al.
Clinical delivery system for intraperitoneal hyperthermic chemotherapy
Cancer Res
(1980)
Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug
Cancer Res
(1984)
Intra-peritoneal chemo-hyperthermia (CHIP): a new therapy in the treatment of the peritoneal seedingsPreliminary report
Int Surg
(1991)
Cited by (22)
Best practice for perioperative management of patients with cytoreductive surgery and HIPEC
2017, European Journal of Surgical OncologyCitation Excerpt :As this procedure is technically challenging with potential high morbidity and mortality up to 12.0–52.0% and 0.9–5.8%, respectively,16 institutional experience is essential for optimal treatment and prevention of adverse events.17 Sugarbaker et al. clearly demonstrated a decrease in 30-day in-hospital morbidity and mortality from 35% to 5% to as low as 19% and 2%, respectively, depending among other things on physician and nursing staff expertise in caring for these patients.8,18 Therefore, centralization of the procedure to specialized institutions is recommended and the German Society for General and Visceral Surgery is certifying centers of competence for surgical treatment of peritoneal malignancies.
Role of hyperthermic intraperitoneal chemotherapy in ovarian cancer
2020, Chinese Clinical Oncology
Copyright © 2011 Elsevier Inc. All rights reserved.